<p>隨着全球市場繼續應對消費者通脹上升和企業盈利強勁的複雜局面，標準普爾 500 指數和納斯達克綜合指數等指數已達到新高，反映出投資者在經濟信號混雜的情況下的信心。在這種環境下，內部持股比例高的成長型公司可能提供吸引人的投資機會，因為它們與股東利益的一致性可能在市場波動中提供韌性和持續表現的潛力。</p>
<h3>全球內部持股比例高的十大成長型公司</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>內部持股比例</strong></td>
<td><strong>盈利增長</strong></td>
</tr>
<tr>
<td>浙江零跑科技 (SEHK:9863)</td>
<td>15.6%</td>
<td>61%</td>
</tr>
<tr>
<td>上海華測導航技術 (SZSE:300627)</td>
<td>24.3%</td>
<td>23.5%</td>
</tr>
<tr>
<td>Pharma Mar (BME:PHM)</td>
<td>11.8%</td>
<td>43.3%</td>
</tr>
<tr>
<td>Novoray (SHSE:688300)</td>
<td>23.6%</td>
<td>28.2%</td>
</tr>
<tr>
<td>老鋪黃金 (SEHK:6181)</td>
<td>35.5%</td>
<td>42.6%</td>
</tr>
<tr>
<td>KebNi (OM:KEBNI B)</td>
<td>38.3%</td>
<td>94.5%</td>
</tr>
<tr>
<td>金電路電子 (TWSE:2368)</td>
<td>31.4%</td>
<td>25.9%</td>
</tr>
<tr>
<td>富林精密 (SZSE:300432)</td>
<td>13.6%</td>
<td>43.7%</td>
</tr>
<tr>
<td>Elliptic Laboratories (OB:ELABS)</td>
<td>24.4%</td>
<td>79%</td>
</tr>
<tr>
<td>Circus (XTRA:CA1)</td>
<td>24.7%</td>
<td>94.8%</td>
</tr>
</tbody>
</table>
<p>點擊這裏查看我們快速增長的全球內部持股比例高的 814 只股票的完整列表。</p>
<p>讓我們從我們的專業篩選器中發現一些寶藏。</p>
<h2>Alsea. de (BMV:ALSEA *)</h2>
<p><strong>Simply Wall St 成長評級：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> Alsea, S.A.B. de C.V. 在拉丁美洲和歐洲經營餐廳，市值為 384.1 億墨西哥比索。</p>
<p><strong>運營：</strong> Alsea 的收入來源包括來自拉丁美洲的食品和飲料銷售 687.8 億墨西哥比索，以及來自歐洲的 289.4 億墨西哥比索的運營收入。</p>
<p><strong>內部持股比例：</strong> 38.9%</p>
<p><strong>盈利增長預測：</strong> 每年 26.1%。</p>
<p>Alsea, S.A.B. de C.V. 展現出作為一家成長型公司的潛力，內部持股比例顯著，報告 2025 年第二季度盈利為 11.3 億墨西哥比索，較去年 2820.3 萬墨西哥比索大幅增長。其年利潤增長預計將超過市場，達到 26.1%，儘管收入增長預計為每年 7.7% 的較温和水平。儘管交易價格略低於公允價值，並且預測的股本回報率較高，但它面臨着利息覆蓋和股價波動的挑戰。</p>
<ul>
<li>點擊這裏訪問我們的完整增長分析報告，以瞭解 Alsea. de 的動態。</li>
<li>我們編制的估值報告表明，Alsea. de 當前的價格可能相當適中。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/810e87af-2a79-4c5e-bbe6-cdbe5b7dda0e/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/810e87af-2a79-4c5e-bbe6-cdbe5b7dda0e/chart/earnings-and-revenue-growth"/></p>
<p>BMV:ALSEA * 截至 2025 年 7 月的盈利和收入增長</p>
<h2>愛博醫療科技 (北京) (SHSE:688050)</h2>
<p><strong>Simply Wall St 成長評級：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> 愛博醫療科技（北京）有限公司專注於創新醫療解決方案，市值為 139.9 億人民幣。</p>
<p><strong>運營：</strong> 該公司主要通過其醫療產品部門產生收入，金額為 14.6 億人民幣。</p>
<p><strong>內部持股比例：</strong> 20.5%</p>
<p><strong>盈利增長預測：</strong> 每年 24.3%。</p>
<p>愛博醫療科技（北京）有望實現顯著增長，預計收入和盈利每年增長超過 20%，超過中國市場平均水平。該公司的股票交易價格低於公允價值 23.5%，分析師預測價格將上漲 51.7%。最近的私募融資籌集了 2.8 億人民幣，表明強大的資本支持。然而，其股本回報率預計將保持在 18.3% 的低水平，最近沒有報告顯著的內部交易活動。</p>
<ul>
<li>點擊這裏深入瞭解愛博醫療科技（北京）的未來增長分析報告。</li>
<li>我們的綜合估值報告提出，愛博醫療科技（北京）的價格可能低於其財務狀況所能證明的水平。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/dc20de00-78ea-4048-94bf-72044b6428d6/chart/ownership-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/dc20de00-78ea-4048-94bf-72044b6428d6/chart/ownership-breakdown"/></p>
<p>SHSE:688050 截至 2025 年 7 月的持股結構</p>
<h2>Canmax Technologies (SZSE:300390)</h2>
<p><strong>Simply Wall St 成長評級：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> Canmax Technologies Co., Ltd. 專注於提供新能源鋰電池材料，市值為 167.5 億人民幣。</p>
<p><strong>運營：</strong> Canmax Technologies Co., Ltd. 主要通過提供新能源鋰電池材料產生收入。</p>
<p><strong>內部持股比例：</strong> 33.7%</p>
<p><strong>盈利增長預測：</strong> 每年 43.8%。</p>
<p>Canmax Technologies 處於增長的有利位置，預計收入和盈利將顯著快於中國市場平均水平。儘管前景積極，但該公司面臨着預測的股本回報率低至 4.9% 和未能由盈利或自由現金流覆蓋的不可持續股息的挑戰。最近對其章程的修訂可能表明戰略轉變，但最近幾個月內部交易活動較少。</p>
<ul>
<li>通過閲讀我們的分析師估計報告，深入瞭解 Canmax Technologies 的表現。</li>
<li>我們的 Canmax Technologies 估值報告中的分析表明，其股價可能高於其估計價值。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/97f013da-1b1b-41ea-9cd4-1b7a19746e9c/chart/ownership-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/97f013da-1b1b-41ea-9cd4-1b7a19746e9c/chart/ownership-breakdown"/></p>
<p>SZSE:300390 截至 2025 年 7 月的持股結構</p>
<h2>將想法轉化為行動</h2>
<ul>
<li>點擊這裏解鎖我們 814 家快速增長的全球內部持股比例高的公司的完整列表。</li>
<li>對其他可能性感興趣？最新的 GPU 需要一種名為鋱的稀土金屬，全球只有 25 家公司在探索或生產它。免費獲取列表。</li>
</ul>
<p><em>這篇來自 Simply Wall St 的文章具有一般性。<strong>我們提供的評論僅基於歷史數據和分析師預測，採用無偏見的方法，我們的文章並不意圖提供財務建議。</strong> 它不構成買入或賣出任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均沒有持倉。該分析僅考慮內部人士直接持有的股票，不包括通過其他工具（如公司和/或信託實體）間接持有的股票。所有預測的收入和收益增長率均以年化（每年）增長率的形式表示，時間範圍為 1-3 年。</em></p>

愛博醫療

零跑汽車

<p>隨着全球市場面臨消費者通脹上升和強勁的企業盈利，標普 500 指數和納斯達克綜合指數已達到新高。內部持股比例高的成長型公司呈現出吸引人的投資機會。值得注意的公司包括浙江零跑科技、KebNi 和 Alsea，這些公司都有顯著的盈利增長預測。例如，Alsea 顯示出 26.1% 的年利潤增長，而愛博醫療科技預計增長超過 20%。儘管面臨挑戰，這些公司可能在波動的市場中提供韌性和持續表現的潛力</p>

<p>As global markets continue to navigate the complexities of rising consumer inflation and robust corporate earnings, indices such as the S&amp;P 500 and Nasdaq Composite have reached new highs, reflecting investor confidence amidst mixed economic signals. In this environment, growth companies with high insider ownership can offer appealing investment opportunities, as their alignment with shareholder interests may provide resilience and potential for sustained performance despite market fluctuations.</p>
<div class="lb-trans"><p>隨着全球市場繼續應對消費者通脹上升和企業盈利強勁的複雜局面，標準普爾 500 指數和納斯達克綜合指數等指數已達到新高，反映出投資者在經濟信號混雜的情況下的信心。在這種環境下，內部持股比例高的成長型公司可能提供吸引人的投資機會，因為它們與股東利益的一致性可能在市場波動中提供韌性和持續表現的潛力。</p>
</div><h3>Top 10 Growth Companies With High Insider Ownership Globally</h3>
<div class="lb-trans"><h3>全球內部持股比例高的十大成長型公司</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Insider Ownership</strong></td>
<td><strong>Earnings Growth</strong></td>
</tr>
<tr>
<td>Zhejiang Leapmotor Technology (SEHK:9863)</td>
<td>15.6%</td>
<td>61%</td>
</tr>
<tr>
<td>Shanghai Huace Navigation Technology (SZSE:300627)</td>
<td>24.3%</td>
<td>23.5%</td>
</tr>
<tr>
<td>Pharma Mar (BME:PHM)</td>
<td>11.8%</td>
<td>43.3%</td>
</tr>
<tr>
<td>Novoray (SHSE:688300)</td>
<td>23.6%</td>
<td>28.2%</td>
</tr>
<tr>
<td>Laopu Gold (SEHK:6181)</td>
<td>35.5%</td>
<td>42.6%</td>
</tr>
<tr>
<td>KebNi (OM:KEBNI B)</td>
<td>38.3%</td>
<td>94.5%</td>
</tr>
<tr>
<td>Gold Circuit Electronics (TWSE:2368)</td>
<td>31.4%</td>
<td>25.9%</td>
</tr>
<tr>
<td>Fulin Precision (SZSE:300432)</td>
<td>13.6%</td>
<td>43.7%</td>
</tr>
<tr>
<td>Elliptic Laboratories (OB:ELABS)</td>
<td>24.4%</td>
<td>79%</td>
</tr>
<tr>
<td>Circus (XTRA:CA1)</td>
<td>24.7%</td>
<td>94.8%</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>內部持股比例</strong></td>
<td><strong>盈利增長</strong></td>
</tr>
<tr>
<td>浙江零跑科技 (SEHK:9863)</td>
<td>15.6%</td>
<td>61%</td>
</tr>
<tr>
<td>上海華測導航技術 (SZSE:300627)</td>
<td>24.3%</td>
<td>23.5%</td>
</tr>
<tr>
<td>Pharma Mar (BME:PHM)</td>
<td>11.8%</td>
<td>43.3%</td>
</tr>
<tr>
<td>Novoray (SHSE:688300)</td>
<td>23.6%</td>
<td>28.2%</td>
</tr>
<tr>
<td>老鋪黃金 (SEHK:6181)</td>
<td>35.5%</td>
<td>42.6%</td>
</tr>
<tr>
<td>KebNi (OM:KEBNI B)</td>
<td>38.3%</td>
<td>94.5%</td>
</tr>
<tr>
<td>金電路電子 (TWSE:2368)</td>
<td>31.4%</td>
<td>25.9%</td>
</tr>
<tr>
<td>富林精密 (SZSE:300432)</td>
<td>13.6%</td>
<td>43.7%</td>
</tr>
<tr>
<td>Elliptic Laboratories (OB:ELABS)</td>
<td>24.4%</td>
<td>79%</td>
</tr>
<tr>
<td>Circus (XTRA:CA1)</td>
<td>24.7%</td>
<td>94.8%</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 814 stocks from our Fast Growing Global Companies With High Insider Ownership screener.</p>
<div class="lb-trans"><p>點擊這裏查看我們快速增長的全球內部持股比例高的 814 只股票的完整列表。</p>
</div><p>Let's uncover some gems from our specialized screener.</p>
<div class="lb-trans"><p>讓我們從我們的專業篩選器中發現一些寶藏。</p>
</div><h2>Alsea. de (BMV:ALSEA *)</h2>
<div class="lb-trans"><h2>Alsea. de (BMV:ALSEA *)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 成長評級：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Alsea, S.A.B. de C.V. operates restaurants across Latin America and Europe with a market cap of MX$38.41 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> Alsea, S.A.B. de C.V. 在拉丁美洲和歐洲經營餐廳，市值為 384.1 億墨西哥比索。</p>
</div><p><strong>Operations:</strong> Revenue segments for Alsea include MX$68.78 billion from food and beverage sales in Latin America and MX$28.94 billion from operations in Europe.</p>
<div class="lb-trans"><p><strong>運營：</strong> Alsea 的收入來源包括來自拉丁美洲的食品和飲料銷售 687.8 億墨西哥比索，以及來自歐洲的 289.4 億墨西哥比索的運營收入。</p>
</div><p><strong>Insider Ownership:</strong> 38.9%</p>
<div class="lb-trans"><p><strong>內部持股比例：</strong> 38.9%</p>
</div><p><strong>Earnings Growth Forecast:</strong> 26.1% p.a.</p>
<div class="lb-trans"><p><strong>盈利增長預測：</strong> 每年 26.1%。</p>
</div><p>Alsea, S.A.B. de C.V. demonstrates potential as a growth company with significant insider ownership, reporting strong Q2 2025 earnings of MXN 1.13 billion, up from MXN 282.03 million the previous year. Its annual profit growth is expected to outpace the market at 26.1%, though revenue growth is projected at a more moderate rate of 7.7% annually. Despite trading slightly below fair value and having high forecasted return on equity, it faces challenges with interest coverage and share price volatility.</p>
<div class="lb-trans"><p>Alsea, S.A.B. de C.V. 展現出作為一家成長型公司的潛力，內部持股比例顯著，報告 2025 年第二季度盈利為 11.3 億墨西哥比索，較去年 2820.3 萬墨西哥比索大幅增長。其年利潤增長預計將超過市場，達到 26.1%，儘管收入增長預計為每年 7.7% 的較温和水平。儘管交易價格略低於公允價值，並且預測的股本回報率較高，但它面臨着利息覆蓋和股價波動的挑戰。</p>
</div><ul>
<li>Click here and access our complete growth analysis report to understand the dynamics of Alsea. de.</li>
<li>The valuation report we've compiled suggests that Alsea. de's current price could be quite moderate.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏訪問我們的完整增長分析報告，以瞭解 Alsea. de 的動態。</li>
<li>我們編制的估值報告表明，Alsea. de 當前的價格可能相當適中。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/810e87af-2a79-4c5e-bbe6-cdbe5b7dda0e/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/810e87af-2a79-4c5e-bbe6-cdbe5b7dda0e/chart/earnings-and-revenue-growth"/></p>
<p>BMV:ALSEA * Earnings and Revenue Growth as at Jul 2025</p>
<div class="lb-trans"><p>BMV:ALSEA * 截至 2025 年 7 月的盈利和收入增長</p>
</div><h2>Eyebright Medical Technology (Beijing) (SHSE:688050)</h2>
<div class="lb-trans"><h2>愛博醫療科技 (北京) (SHSE:688050)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 成長評級：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Eyebright Medical Technology (Beijing) Co., Ltd. operates in the medical technology sector, focusing on innovative healthcare solutions, with a market cap of CN¥13.99 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 愛博醫療科技（北京）有限公司專注於創新醫療解決方案，市值為 139.9 億人民幣。</p>
</div><p><strong>Operations:</strong> The company generates revenue primarily from its medical products segment, amounting to CN¥1.46 billion.</p>
<div class="lb-trans"><p><strong>運營：</strong> 該公司主要通過其醫療產品部門產生收入，金額為 14.6 億人民幣。</p>
</div><p><strong>Insider Ownership:</strong> 20.5%</p>
<div class="lb-trans"><p><strong>內部持股比例：</strong> 20.5%</p>
</div><p><strong>Earnings Growth Forecast:</strong> 24.3% p.a.</p>
<div class="lb-trans"><p><strong>盈利增長預測：</strong> 每年 24.3%。</p>
</div><p>Eyebright Medical Technology (Beijing) is poised for substantial growth, with revenue and earnings forecasted to expand over 20% annually, surpassing the Chinese market averages. The company's shares are trading at 23.5% below fair value, with analysts predicting a 51.7% price increase. Recent private placements raised CNY 280 million, indicating strong capital backing. However, its return on equity is expected to remain low at 18.3%, and no significant insider trading activity has been reported recently.</p>
<div class="lb-trans"><p>愛博醫療科技（北京）有望實現顯著增長，預計收入和盈利每年增長超過 20%，超過中國市場平均水平。該公司的股票交易價格低於公允價值 23.5%，分析師預測價格將上漲 51.7%。最近的私募融資籌集了 2.8 億人民幣，表明強大的資本支持。然而，其股本回報率預計將保持在 18.3% 的低水平，最近沒有報告顯著的內部交易活動。</p>
</div><ul>
<li>Delve into the full analysis future growth report here for a deeper understanding of Eyebright Medical Technology (Beijing).</li>
<li>Our comprehensive valuation report raises the possibility that Eyebright Medical Technology (Beijing) is priced lower than what may be justified by its financials.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏深入瞭解愛博醫療科技（北京）的未來增長分析報告。</li>
<li>我們的綜合估值報告提出，愛博醫療科技（北京）的價格可能低於其財務狀況所能證明的水平。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/dc20de00-78ea-4048-94bf-72044b6428d6/chart/ownership-breakdown" alt="" original-src="https://images.simplywall.st/company/dc20de00-78ea-4048-94bf-72044b6428d6/chart/ownership-breakdown"/></p>
<p>SHSE:688050 Ownership Breakdown as at Jul 2025</p>
<div class="lb-trans"><p>SHSE:688050 截至 2025 年 7 月的持股結構</p>
</div><h2>Canmax Technologies (SZSE:300390)</h2>
<div class="lb-trans"><h2>Canmax Technologies (SZSE:300390)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 成長評級：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Canmax Technologies Co., Ltd. specializes in providing new energy lithium battery materials and has a market cap of CN¥16.75 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> Canmax Technologies Co., Ltd. 專注於提供新能源鋰電池材料，市值為 167.5 億人民幣。</p>
</div><p><strong>Operations:</strong> Canmax Technologies Co., Ltd. generates its revenue primarily from the provision of new energy lithium battery materials.</p>
<div class="lb-trans"><p><strong>運營：</strong> Canmax Technologies Co., Ltd. 主要通過提供新能源鋰電池材料產生收入。</p>
</div><p><strong>Insider Ownership:</strong> 33.7%</p>
<div class="lb-trans"><p><strong>內部持股比例：</strong> 33.7%</p>
</div><p><strong>Earnings Growth Forecast:</strong> 43.8% p.a.</p>
<div class="lb-trans"><p><strong>盈利增長預測：</strong> 每年 43.8%。</p>
</div><p>Canmax Technologies is positioned for growth, with revenue and earnings expected to grow significantly faster than the Chinese market averages. Despite this positive outlook, the company faces challenges with low forecasted return on equity at 4.9% and unsustainable dividends not covered by earnings or free cash flows. Recent amendments to its articles of association may indicate strategic shifts, but insider trading activity has been minimal in recent months.</p>
<div class="lb-trans"><p>Canmax Technologies 處於增長的有利位置，預計收入和盈利將顯著快於中國市場平均水平。儘管前景積極，但該公司面臨着預測的股本回報率低至 4.9% 和未能由盈利或自由現金流覆蓋的不可持續股息的挑戰。最近對其章程的修訂可能表明戰略轉變，但最近幾個月內部交易活動較少。</p>
</div><ul>
<li>Get an in-depth perspective on Canmax Technologies' performance by reading our analyst estimates report here.</li>
<li>The analysis detailed in our Canmax Technologies valuation report hints at an inflated share price compared to its estimated value.</li>
</ul>
<div class="lb-trans"><ul>
<li>通過閲讀我們的分析師估計報告，深入瞭解 Canmax Technologies 的表現。</li>
<li>我們的 Canmax Technologies 估值報告中的分析表明，其股價可能高於其估計價值。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/97f013da-1b1b-41ea-9cd4-1b7a19746e9c/chart/ownership-breakdown" alt="" original-src="https://images.simplywall.st/company/97f013da-1b1b-41ea-9cd4-1b7a19746e9c/chart/ownership-breakdown"/></p>
<p>SZSE:300390 Ownership Breakdown as at Jul 2025</p>
<div class="lb-trans"><p>SZSE:300390 截至 2025 年 7 月的持股結構</p>
</div><h2>Turning Ideas Into Actions</h2>
<div class="lb-trans"><h2>將想法轉化為行動</h2>
</div><ul>
<li>Unlock our comprehensive list of 814 Fast Growing Global Companies With High Insider Ownership by clicking here.</li>
<li>Interested In Other Possibilities? The latest GPUs need a type of rare earth metal called Terbium and there are only 25 companies in the world exploring or producing it. Find the list for free.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏解鎖我們 814 家快速增長的全球內部持股比例高的公司的完整列表。</li>
<li>對其他可能性感興趣？最新的 GPU 需要一種名為鋱的稀土金屬，全球只有 25 家公司在探索或生產它。免費獲取列表。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.</em></p>
<div class="lb-trans"><p><em>這篇來自 Simply Wall St 的文章具有一般性。<strong>我們提供的評論僅基於歷史數據和分析師預測，採用無偏見的方法，我們的文章並不意圖提供財務建議。</strong> 它不構成買入或賣出任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均沒有持倉。該分析僅考慮內部人士直接持有的股票，不包括通過其他工具（如公司和/或信託實體）間接持有的股票。所有預測的收入和收益增長率均以年化（每年）增長率的形式表示，時間範圍為 1-3 年。</em></p>
</div>

2025 年 7 月全球增長型公司及其高內部持股情況